References
- 1World Health Organization. Global status report on non-communicable disease; 2014.
- 2Di Cesare M, Khang Y, Asaria P, et al. Inequalities in non-communicable diseases and effective responses. Lancet. 2013; 381(9866): 585–597. DOI: 10.1016/S0140-6736(12)61851-0
- 3World Health Organization. Global health estimates 2014 summary table; 2014.
- 4Institute for Health Metrics and Evaluation. Global Burden of Disease (GDB) Compare; 2016. Retrieved from
https://vizhub.healthdata.org/gbd-compare/ . (accessed 07/03, 2019). - 5World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016. 2018.
- 6Moran A, Forouzanfar M, Sampson U, et al. The epidemiology of cardiovascular diseases in sub-Saharan Africa: The Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Prog Cardiovasc Dis. 2013; 56(3): 234–239. DOI: 10.1016/j.pcad.2013.09.019
- 7World Health Organization, World Economic Forum. From burden to ‘best buys’: Reducing the economic impact of NCDs in low- and middle-income countries; 2011.
- 8Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 7 October 2016; 37(38): 2893–2962.
- 9Jacobs MS, van Hulst M, Adeoye AM, et al. Atrial Fibrillation in Africa – An Underreported and Unrecognized Risk Factor for Stroke: A Systematic Review. Global Heart. 2019; 14: 269–279. DOI: 10.1016/j.gheart.2019.04.003
- 10Murphy A, Banerjee A, Breithardt G, et al. The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. Glob Heart. December 2017; 12(4): 273–284. DOI: 10.1016/j.gheart.2017.01.015
- 11Tieleman RG, Plantinga Y, Rinkes D, et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace. 2014; 16: 1291–5. DOI: 10.1093/europace/euu057
- 12Taggar JS, Coleman T, Leiws S, Heneghan C, Jones M. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: A systematic review and meta-analysis. European Journal of Preventive Cardiology. 2016: 23; 1330–1338. DOI: 10.1177/2047487315611347
- 13Healey JS, Connoly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. New Eng J Med. 2012; 366: 120–129. DOI: 10.1056/NEJMoa1105575
- 14Potpara TS, Polovina MM, Marinkovic JM, Lip GY. Comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol. 2013; 168: 4744–4749. DOI: 10.1016/j.ijcard.2013.07.234
- 15Flaker GC, Belwe K, Beckamn K, et al. Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149: 657–663. DOI: 10.1016/j.ahj.2004.06.032
- 16De Vos CB, Breithardt G, Camm J, et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. Am Heart J. 2012; 163: 887–93. DOI: 10.1016/j.ahj.2012.02.015
- 17Glotzer TV, Daoud EG, Wyse G, et al. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk. Circulation: Arrhytmia and Electrophysiology. 2009; 2: 474–480. DOI: 10.1161/CIRCEP.109.849638
- 18Birabi B, Oke K, Dienye P, Okafur, OC. Cost Burden of Post Stroke Condition in Nigeria: A Pilot Study. Global Journal of Health Science. 2011; 4: 17–22. DOI: 10.5539/gjhs.v4n6p17
- 19Temu T, Lane K, Shen C, et al. Clinical characteristics and 12-month outcomes of patients with valvular and nonvalvular atrial fibrillation in Kenya. PLoS ONE. 2017; 12(9):
e0185204 . DOI: 10.1371/journal.pone.0185204 - 20Alkali N, Bwala S, Akano A. Stroke risk factors, subtypes, and 30-day case fatality in Abuja, Nigeria. Nigerian Medical Journal. 2013; 54(2): 129–135. DOI: 10.4103/0300-1652.110051
- 21Hart R, Benavente O, McBride R, Aguilar M. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Ann Intern Med. 1999; 131(7): 492–501. DOI: 10.7326/0003-4819-131-7-199910050-00003
- 22Hart R, Pearce L, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857–867. DOI: 10.7326/0003-4819-146-12-200706190-00007
- 23National Bureau of Statistics. Demographics of Nigeria. 2018. Retrieved from
https://www.nigerianstat.gov.ng . (accessed 11/10, 2019). - 24Owolabi M. Impact of stroke on health-related quality of life in diverse cultures: The Berlin-Ibadan multicenter international study. Health Qual Life Outcomes. 2011; 9: 81. DOI: 10.1186/1477-7525-9-81
- 25Wang K, Li H, Kwong WJ, et al. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017; 6:
e006703 . DOI: 10.1161/JAHA.117.006703 - 26Sullivan P, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006; 26(4): 410–20. DOI: 10.1177/0272989X06290495
- 27Baeten S, van Exel N, Dirks M, et al. Lifetime health effects and medical costs of integrated stroke services – a non-randomized controlled cluster-trial based life table approach. Cost effectiveness and resource allocation. 2010; 8(1): 21. DOI: 10.1186/1478-7547-8-21
- 28Jacobs M, Kaasenbrood F, Postma M, van Hulst M, Tieleman R. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. 2018; 20(1): 12–18.
- 29World Health Organization. World Health Organization CHOosing Interventions that are Cost-Effective (CHOICE); 2014. Retrieved from
www.who.int/choice/cost-effectiveness/en . (accessed 11/19, 2019). - 30Bergh M, Marais C, Miller-Jansön H, Salie F, Stand M. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. S Afr Med J. 2013; 103(4): 241–245. DOI: 10.7196/SAMJ.6471
- 31World Bank. GDP per capita Nigeria 2019 (current US$). Retrieved from
www.data.worldbank.org . (accessed 05/23 2021). - 32Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. The Lancet. 2014; 383(955): 962. DOI: 10.1016/S0140-6736(13)62343-0
- 33Svennberg E, Engdahl J, Al-Khalili F, et al. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 23 2015; 131: 2176–2184. DOI: 10.1161/CIRCULATIONAHA.114.014343
- 34Li K, White F, Tipoe T, et al. The Current State of Mobile Phone Apps for Monitoring Heart Rate, Heart Rate Variability, and Atrial Fibrillation: Narrative Review. JMIR Mhealth Uhealth. 2019; 7(2):
e11606 . DOI: 10.2196/11606 - 35Semakula JR, Mouton JP, Jorgensen A, et al. A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS One. 29 2020; 15(1):
e0227458 . DOI: 10.1371/journal.pone.0227458 - 36Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet. 2010; 376(9745): 975–983. DOI: 10.1016/S0140-6736(10)61194-4
- 37Potpara TS, Polovina MM, Marinkovic JM, Lip GY. Comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol. 2013; 168: 4744–4749. DOI: 10.1016/j.ijcard.2013.07.234
- 38Flaker GC, Belwe K, Beckamn K, et al. Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149: 657–663. DOI: 10.1016/j.ahj.2004.06.032
- 39World Health Organization. Model List of Essential Medicines, 21st List. 2019(21).
- 40World Health Organization. Exploring the expansion of the Medicines Patent Pool’s mandate to patented essential medicines. Chapter 5 – Patented medicines that have clinical benefits but did not meet the EML Expert Review committee’s comparative cost-effectiveness criterion: Case study on novel oral anticoagulants; 2018.
- 41Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data. Lancet. 2016; 387: 61–69. DOI: 10.1016/S0140-6736(15)00469-9